ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,180.74
1.03%
US Tech 100
17,610.00
0.00%
Dow Jones
38,852.27
0.46%
Brent Oil
83.205
-0.32%
Bitcoin
63,775.56
0.96%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. PepGen Inc (PEPG) Quote

PepGen Inc

PepGen Inc (PEPG)

PepsiCo Inc
13.95
0.00
(0.00%)
Closed May 07 4:00PM
Delayed by 15 minutes
0.00
0.00
(0.00%)
After Hours: -
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
13.95
Bid
6.20
Ask
19.52
Volume
-
0.00 Day's Range 0.00
3.72 52 Week Range 17.51
Market Cap
451.345M
Previous Close
13.95
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
88,505
Shares Outstanding
32,354,495
Dividend Yield
-
PE Ratio
-5.74
Earnings Per Share (EPS)
-2.43
Revenue
-
Net Profit
-78.63M

About PepGen Inc

PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases. PepGen Inc is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapeutics with the goal of transforming the treatment of severe neuromuscular and neurologic diseases.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
pepgen.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
PepGen Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker PEPG. The last closing price for PepGen was $13.95. Over the last year, PepGen shares have traded in a share price range of $ 3.72 to $ 17.51.

PepGen currently has 32,354,495 shares outstanding. The market capitalization of PepGen is $451.35 million. PepGen has a price to earnings ratio (PE ratio) of -5.74.

PEPG Latest News

More News

PepGen to Participate in Upcoming Investor Conferences

BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of...

March 13 2024
GlobeNewswire Inc.

PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

BOSTON, March 13, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of...

March 13 2024
GlobeNewswire Inc.

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

March 06 2024
Edgar (US Regulatory)

PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments

- Enrollment completed for PGN-EDO51 5 mg/kg cohort in CONNECT1-EDO51 Phase 2 clinical trial in DMD patients. The Company expects to announce preliminary data from the 5 mg/kg dose cohort in...

March 06 2024
GlobeNewswire Inc.

Form 8-K - Current report

March 06 2024
Edgar (US Regulatory)

Form 8-K - Current report

March 04 2024
Edgar (US Regulatory)

PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

BOSTON, March 04, 2024 (GLOBE NEWSWIRE) -- PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of...

March 04 2024
GlobeNewswire Inc.

Form 4 - Statement of changes in beneficial ownership of securities

March 01 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
12.1818.521665250611.7715.2211.779866714.04191148CS
41.5812.772837510112.3715.2210.2156089512.65906253CS
120.836.326219512213.1217.5110.2158850514.20716793CS
268.9176.2376237625.0517.513.7210387111.07683056CS
52-1.04-6.9379586390914.9917.513.727950410.20511436CS
156-1.65-10.576923076915.6203.7210458911.21787741CS
260-1.65-10.576923076915.6203.7210458911.21787741CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AAGRAfrican Agriculture Holdings Inc
$ 0.4005
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 63.53
(0.00%)
0
AADIAadi Bioscience Inc
$ 2.00
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 11.802
(0.00%)
0
AACGATA Creativity Global
$ 0.87001
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.4005
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 63.53
(0.00%)
0
AADIAadi Bioscience Inc
$ 2.00
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 11.802
(0.00%)
0
AACGATA Creativity Global
$ 0.87001
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.4005
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 63.53
(0.00%)
0
AADIAadi Bioscience Inc
$ 2.00
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 11.802
(0.00%)
0
AACGATA Creativity Global
$ 0.87001
(0.00%)
0

PEPG Discussion

View Posts
Monksdream Monksdream 2 months ago
PEPG 10Q due 3/22
👍️0
Monksdream Monksdream 3 months ago
Early Barchart 100
https://www.barchart.com/stocks/performance/percent-change/advances?timeFrame=today&viewName=main&screener=overall&orderBy=percentChange&orderDir=desc
👍️0

Your Recent History

NASDAQ
PEPG
PepGen
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved